Kidney Carcinoma — Trials

Kidney Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,681 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 398
Recruiting: 202
Ph III recruiting: 17
Growth YoY: +1.2%
Industry share: 32%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 39.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (283)

clinicaltrialsPublishedShowing 51–100 of 113 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05219318	Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors(SPICI)	active not recruiting	Phase 3	22	University Hospital, BordeauxOTHER	1	Jun 4, 2025	clinicaltrials
NCT03592472	A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)	recruiting	Phase 3	413	Xynomic Pharmaceuticals, Inc.